Venture capital

China-US biotech startup raises money for flu drug

Lilly Asia Ventures, Oceanpine Capital, Matrix Partners China are betting on Ansun BioPharma to kill the virus on your respiratory tract.

China-US based biotech company Ansun BioPharma raised $80 million in its series B funding round to support the phase three clinical trial for its newly-developed medication, the company said on Monday.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media